Complications Associated with Chronic Steroid Use

Complications in Regional Anesthesia and Pain Medicine

Volumn , Issue , 2007, Pages 331-339

  Huntoon, Marc A ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449676743     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-2392-0.50036-4     Document Type: Chapter

References (56)

1. Chrousos GP Adrenocorticosteroids and adrenocortical antagonists. Basic and Clinical Pharmacology 2004, 641-660. Lang Medical Books/McGraw-Hill, New York. Ninth Edition. B.G. Katzung (Ed.).
2. Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone): Compound E and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949, 24:181-197.
3. Hollander JL, Brown EM, Jessar RA, et al. Hydrocortisone and cortisone injected into arthritic joints. JAMA 1951, 147:1629-1635.
4. Winnie AP, Hartman JT, Meyers HL, et al. Pain Clinic II: Intradural and extradural corticosteroids for sciatica. Anesth Analg 1972, 51:990-999.
5. Jacoby RK The effect of hydrocortisone acetate on adult human articular cartilage. J Rheumatol 1976, 3:384-389.
6. Friedman DM, Moore ME The efficacy of intraarticular steroids in osteoarthritis: A double blind study. J Rheumatol 1980, 7:850-856.
7. Devor M, Govrin-Lippmann R, Raber P Corticosteroids suppress ectopic neural discharge originating in experimental neuromas. Pain 1985, 22:127-137.
8. Anderson B, Kaye S Treatment of flexor tenosynovitis of the hand ("trigger finger") with corticosteroids: A prospective study of the response to local injection. Arch Intern Med 1991, 151:153-156.
9. Williams JM, Brandt KD Triamcinolone hexacetonide protects against fibrillation and osteophyte formation following chemically induced cartilage damage. Arthritis amp; Rheumatism 1985, 28:1267-1274.
10. Buckley LM, Marquez M, Hudson J, et al. Variations in physician's judgment about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 1998, 25:2195-2202.
11. Nelson DA, Vates TS, Thomas RB Complications from intrathecal steroid therapy in patients with multiple sclerosis. Acta Neurol Scand 1973, 49(2):176-188.
12. Bedi SS, Ellis W Spontaneous rupture of the calcaneal tendon in rheumatoid arthritis after local steroid injection. Ann Rheum Dis 1970, 29(5):494-495.
13. Barnes PJ, Adcock I Anti-inflammatory actions of steroids: Molecular mechanisms. TIPS 1993, 14:436-441.
14. Nasser SMS, Ewan PW Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. BMJ 2001, 322:1589-1591.
15. Weinstein RS, Nicholas RW, Manolagas SC Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000, 85:2907-2912.
16. Clinkscales A, Cleary JD Steroid-induced avascular necrosis. Annals of Pharmacotherapy 2002, 36:1105.
17. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogenic bone marrow transplantation: Analysis of risk factors for 4388 patients by the Societe Francois de Griffe de Moelle. Br J Haematology 1997, 97:865-870.
18. Marsh JCW, Zomas A, Hows JM, et al. Avascular necrosis after treatment of aplastic anemia with anti-lymphocyte globulin and high dose methylprednisolone. Br J Haematology 1993, 84:731-735.
19. Bracken MB, Shepard MJ, Collins WF, et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: Results of the Second National Acute Spinal Cord Injury Study. NEJM 1990, 322:1405-1411.
20. Wing PC, Nance P, Connell DG, et al. Risk of avascular necrosis following short term megadose methylprednisolone treatment. Spinal Cord 1998, 36:633-636.
21. Agarwala S, Jain D, Joshi VR, et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip: A prospective open-label study. Rheumatology 2005, 44:352-359.
22. Wald JJ The effects of toxins on muscle: Clinical neurobehavioral Toxicology. Neurology Clinics 2000, 18(3):695-717.
23. Singleton JR, Baker BL, Thorburn A Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 2000, 141:2945-2950.
24. Kanda F, Takatani K, Okuda S, et al. Preventive effects of insulinlike growth factor-1 on steroid-induced muscle atrophy. Muscle Nerve 1999, 22:213-217.
25. Kanda F, Okuda S, Matsushita T, et al. Steroid myopathy: Pathogenesis and effects of growth hormone and insulin-like growth factor-1 administration. Hormone Research 2001, 56(Suppl 1):24-28.
26. Oshima Y, Kuroda Y, Kunishige M, et al. Oxidative stress-associated mitochondrial dysfunction in corticosteroid-treated muscle cells. Muscle amp; Nerve 2004, 30:49-54.
27. Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology 1997, 48:1234-1238.
28. Braith RW, Welsch MA, Mills RM, et al. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc 1998, 30:483-489.
29. Mitchell MJ, Baz MA, Fulton MN, et al. Resistance training prevents vertebral osteoporosis in lung transplant recipients. Transplantation 2003, 76:557-562.
30. Chromiak JA, Vandenburgh HH Glucocorticoid-induced skeletal muscle atrophy in vitro is attenuated by mechanical stimulation. Am J Physiol 1992, 262:C1471-C1477.
31. Ettinger B, Pressman A, Shah HA Who bears responsibility for glucocorticoid-exposed patients in a large health maintenance organization?. J Managed Care Pharm 2001, 7:228-232.
32. Hofbauer LC, Gori F, Riggs L Stimulation of OPG ligand and inhibition of OPG production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382-4389.
33. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002, 109:1041-1048.
34. Dovio A, Perazzolo L, Giangiacomo O, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004, 89:4923-4928.
35. Sambrook PN How to prevent steroid induced osteoporosis. Ann Rheum Dis 2004, 64:176-178.
36. Cohen D, Adachi JD The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biology 2004, 88:337-349.
37. DeSio JM Epidural steroid injections. Principles and Practice of Pain Medicine 2004, 655-656. McGraw-Hill, New York. Second Edition. C.A. Warfield, Z.H. Bajwa (Eds.).
38. Knight CL, Burnell JC Systemic side effects of extradural steroids. Anaesthesia 1980, 35:593-594.
39. Gorski DW, Rao TK, Glisson SN, et al. Epidural triamcinolone and adrenal response to stress. Anesthesiology 1981, 55:A147.
40. Abrams SE, O'Connor TC Complications associated with epidural steroid injections. Reg Anesth 1996, 21:149-162.
41. Scanlon PD, Connett JE, Wise RA, et al. Loss of bone density with inhaled triamcinolone in lung health study II. Am J Respir Crit Care Med 2004, 170:1302-1309.
42. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis amp; Rheumatism 2001, 44:1496-1503.
43. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633.
44. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
45. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. NEJM 1997, 337:382-387.
46. Saag KG, Emkey R, Schnitzer T, et al. Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis. NEJM 1998, 339:292-299.
47. Adachi R, Saag K, Delmas P, et al. Two-year effects of alendronate on bone mineral density and vertebral fractures in patients receiving glucocorticoids. Arthritis Rheum 2001, 44:202-211.
48. Aldrete JA Chronic adhesive arachnoiditis (Letter to the editor). Br J Anesthes 2004, 93:301-303.
49. Aldrete JA Neurological deficits and arachnoiditis following neuroaxial anesthesia. Acta Anaesthesiol Scand 2003, 47:3-12.
50. Nelson DA, Landau WM Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports. J Neurol Neurosurg Psychiatry 2001, 70:433-443.
51. Moen V, Dahlgren N, Irestedt L Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004, 101:950-959.
52. Abram S, O'Connor T Complications associated with epidural steroid injections. Reg Anesth 1996, 21:149-162.
53. Latham JM, Fraser RD, Moore RJ, et al. The pathologic effects of intrathecal betamethasone. Spine 1997, 22:1558-1562.
54. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. NEJM 2000, 343:1514-1519.
55. Wright MH, Denney LC A comprehensive review of spinal arachnoiditis. Orthop Nursing 2003, 22(3):215-219.
56. Gundry CR, Fritts HM Magnetic resonance imaging of the musculoskeletal system: The spine: Part 8, section 3. Clin Orthopedics amp; Related Research 1998, 346:262-278.